QTX-2101, an oral arsenic trioxide, received FDA fast track designation for acute promyelocytic leukemia, aiming to simplify ...

Discover how antibody-drug conjugates (ADCs) are transforming treatment strategies for gastrointestinal cancers, enhancing ...

IFx-2.0, an innate immune agonist, targets resistance to immune checkpoint inhibitors in advanced cutaneous melanoma, receiving FDA orphan drug designation. Phase 1 trials showed IFx-2.0's safety and ...

Gemogenovatucel-T is a DNA-engineered, triple-function immunotherapy that utilizes a patient's autologous tumor cells as a source for the complete matrix of tumor-related clonal signals. Its mechanism ...

The FDA is reviewing zanzalintinib combined with atezolizumab for metastatic colorectal cancer, with a PDUFA target date of December 3, 2026. The STELLAR-303 trial showed significant overall survival ...

CD47 expression levels may predict evorpacept efficacy in HER2-positive metastatic breast cancer, especially in heavily pretreated patients. Evorpacept combined with zanidatamab shows promising ...

On January 12, NP-G2-044 (Prilukae), a novel oral fascin inhibitor earned ODD for the treatment of pancreatic cancer. This designation covers the use of the agent as monotherapy and in combination ...

This opening segment establishes the clinical context for a 66 year old man with well differentiated, non functioning, ...

The FDA approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), ...

BI-1808 and pembrolizumab combination shows a 24% ORR in recurrent ovarian cancer, surpassing pembrolizumab monotherapy's 8% ...

Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming ...

The LARA trial (NCT04699071), a multi-center, single-arm, phase 2 study, found that combining pembrolizumab (Keytruda) with ...